Hacia un consenso de especialistas para definirlo | 09 OCT 17

Síndrome crónico de falta de aire

La falta de aire que persiste a pesar del tratamiento de la causa subyacente es problemática. Su identificación como un síndrome la haría más visible. En el artículo se proponen los criterios para este síndrome
Autor/a: Johnson MJ, Yorke J, Hansen-Flaschen J Eur Respir J 2017; 49: 1602277
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas


1 Currow DC, Plummer JL, Crockett A, et al. A community population survey of prevalence and severity of dyspnea in adults. J Pain Symptom Manage 2009; 38: 533–545.

2 Harstall C, Ospina M. How prevalent is chronic pain? Pain Clin Upd 2003; 11: 1–4.

3 Addison RG. Chronic pain syndrome. Am J Med 1984; 77: 54–58.

4 Harper D. Online etymology dictionary. www.etymonline.com Date last accessed: November 13, 2016.

5 Pratter MR, Abouzgheib W, Akers S, et al. An algorithmic approach to chronic dyspnea. Respir Med 2011; 105:1014–1021.

6 Currow DC, Smith J, Davidson PM, et al. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. J Pain Symptom Manage 2010; 39: 680–690.

7 Ahmadi Z, Lundstrom S, Janson C, et al. End-of-life care in oxygen-dependent COPD and cancer: a national population-based study. Eur Respir J 2015; 46: 1190–1193.

8 Booth S, Silvester S, Todd C. Breathlessness in cancer and chronic obstructive pulmonary disease: using a qualitative approach to describe the experience of patients and carers. Palliat Support Care 2003; 1: 337–344.

9 Disler RT, Green A, Luckett T, et al. Experience of advanced chronic obstructive pulmonary disease: metasynthesis of qualitative research. J Pain Symptom Manage 2014; 48: 1182–1199.

10 Gysels M, Higginson IJ. Access to services for patients with chronic obstructive pulmonary disease: the invisibility of breathlessness. J Pain Symptom Manage 2008; 36: 451–460.

11 Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434–1440.

12 Smith A, Currow DC, Abernethy AP, et al. Prevalence and outcomes of breathlessness in older adults: a national population study. J Am Geriatr Soc 2016; 64: 2035–2041.

13 Hammond EC. Some preliminary findings on physical complaints from a prospective study of 1,064,004 men and women. Am J Public Health Nations Health 1964; 54: 11–23.

14 Waller K, Kaprio J, Kujala UM. Dyspnea and all-cause mortality: 28-yr follow-up study among adult twins. Med Sci Sports Exerc 2014; 46: 1538–1545.

15 Niska R, Bhuiya F, Xu J. National Hospital Ambulatory Medical Care Survey: 2007 emergency department summary. Natl Health Stat Report 2010; 1–31.

16 Langlo NM, Orvik AB, Dale J, et al. The acute sick and injured patients: an overview of the emergency department patient population at a Norwegian University Hospital Emergency Department. Eur J Emerg Med 2014; 21: 175–180.

17 Currow DC, Abernethy AP, Allcroft P, et al. The need to research refractory breathlessness. Eur Respir J 2016; 47:342–343.

18 Currow DC, Abernethy AP, Ko DN. The active identification and management of chronic refractory breathlessness is a human right. Thorax 2014; 69: 393–394.

19 Booth S, Bausewein C, Higginson I, et al. Pharmacological treatment of refractory breathlessness. Expert Rev Respir Med 2009; 3: 21–36.

20 Johnson MJ, Bland JM, Oxberry SG, et al. Clinically important differences in the intensity of chronic refractory breathlessness. J Pain Symptom Manage 2013; 46: 957–963.

21 Ekstrom M, Nilsson F, Abernethy AA, et al. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thorac Soc 2015; 12: 1079–1092.

22 Ekstrom MP, Abernethy AP, Currow DC. The management of chronic breathlessness in patients with advanced and terminal illness. BMJ 2015; 349: g7617.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2022